PMA device
Supera Peripheral Stent System
Abbott Vascular (Idef Technologies Inc) · Stent, Superficial Femoral Artery (NIP, Class III) · First FDA decision Mar 28, 2014, newest Dec 9, 2025Peripheral artery disease
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
11
PMA pathway
Device trials
19
Naming "Supera"
MAUDE reports
2,546
Brand "Supera", since 2015
PubMed studies
132
Mentioning "Supera"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Supera Peripheral Stent System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 6 of 11 decisions filed under this name.
- Supera Peripheral Stent SystemPMA supplement
P120020-S034 · Decided Dec 9, 2025 · 211 days after receipt · Normal 180 Day Track No User Fee
Device type: STENT, SUPERFICIAL FEMORAL ARTERY (NIP) · Cardiology
5 more FDA decisions with a free account
Older decisions: P120020-S006, P120020-S003, P120020-S002, P120020-S001, P120020
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Percutaneous Transluminal Angioplasty (PTA) of the Carotid Artery Concurrent with StentingNational analysisReview closedCAG-00085R8Updated Sep 21, 2026
- Percutaneous Transluminal Angioplasty (PTA) of the Carotid Artery Concurrent with StentingNational analysisReview closedCAG-00085R7Updated Sep 21, 2026
- Percutaneous Transluminal Angioplasty (PTA) of the Carotid Artery Concurrent with StentingNational analysisReview closedCAG-00085R6Updated Sep 21, 2026
- Percutaneous Transluminal Angioplasty (PTA) of the Carotid Artery Concurrent with StentingNational analysisReview closedCAG-00085R3Updated Sep 21, 2026
- Carotid Artery Stenting in Post-Approval StudiesNational analysisReview closedCAG-00259NUpdated Sep 17, 2026
- Carotid Artery StentingNational analysisReview closedCAG-00085RUpdated Sep 17, 2026
- Percutaneous Transluminal Angioplasty (PTA) of the Carotid Artery Concurrent with StentingNational analysisReview closedCAG-00085NUpdated Sep 15, 2026
Clinical trials
Device studies on ClinicalTrials.gov that name "Supera", any status and sponsor, newest update first.
- A Study Evaluating the Endovascular Treatment of Subjects With Stenotic or Restenotic Lesions of the Common Femoral Artery With the Supera Vascular Mimetic Implant Compared to Surgical Common Femoral Artery EndarterectomyPivotal-lookingActive, not recruiting
KANDO ResearchAcademic, hospital or other
NCT04349657 · 286 participants (planned) · Start May 5, 2020 · Primary completion May 2027
Device: Supera Peripheral Stent System treatment group · For: Peripheral Arterial Disease
Sites: Aalst, Belgium; Bonheiden, Belgium; Dendermonde, Belgium · 13 sites in all
18 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Supera", and for the whole product code for context.
This brand
2,546 reports: 1,187 malfunction, 1,307 injury, 52 death
Whole product code NIP
9,363 reports: 4,911 malfunction, 4,303 injury, 147 death
Newest reports for this brand
- SUPERAInjury
2024168-2026-04187 · Received Oct 28, 2026 · Event dated Oct 15, 2026
Device type: Stent, Superficial Femoral Artery (NIP)
Device problem as coded: Material Separation; Stretched; Difficult or Delayed Activation
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
4 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Supera"[tiab]. The summary above synthesizes these.
- [Not Available].
Ancona C, Michelozzi P · Recenti Prog Med · 2024Editorial, English Abstract
- Efficacy of Supera Stent in the Treatment of Complex Femoropopliteal Artery Lesions: A Short-Term Result Analysis of Real-World Evidence.
Tang X, Ma H, Zhou G, et al. · Ann Vasc Surg · 2024Comparative Study
- SUPERA Stenting in the Common Femoral Artery: Early Experience and Practical Considerations.
Tao MJ, Gotra A, Tan KT, et al. · Vasc Endovascular Surg · 2022
- Supera stent implantation for the treatment of isolated popliteal artery disease systematic review and evaluation of current endovascular strategies.
Salamaga S, Stwpak H, Krasiski Z · Pol Przegl Chir · 2022Systematic Review
- SUPERA stent placement for salvaging early recurrent arteriovenous graft thrombosis after percutaneous transluminal angioplasty: A single-center study.
Lee HN, Park SJ, Cho Y, et al. · J Vasc Access · 2024
- Stent Design Affects Femoropopliteal Artery Deformation.
MacTaggart J, Poulson W, Seas A, et al. · Ann Surg · 2019Comparative Study, Evaluation Study
- Removal of Partially Deployed Supera Stents: Case-Based Review and Technical Considerations.
Martin G, Antonietti A, Patrone L · J Endovasc Ther · 2022Review
- The Supera Interwoven Nitinol Stent as a Flow Diverting Device in Popliteal Aneurysms.
van de Velde L, Groot Jebbink E, Zambrano BA, et al. · Cardiovasc Intervent Radiol · 2022
- Repeated Supera stent fracture following stenting for popliteal artery occlusion: a case report.
Lee BC, Park C, Kim HO, et al. · J Int Med Res · 2025Case Reports
- Midterm Results of the Supera Stent for the Treatment of Femoropopliteal Occlusive Disease.
Low J, Shih T, Lu E, et al. · Ann Vasc Surg · 2022
- A multicenter prospective observational study appraising the effectiveness of the Supera stent after subintimal recanalization of femoro-popliteal artery occlusion: The SUPERSUB II study.
Palena LM, Isernia G, Parlani G, et al. · Catheter Cardiovasc Interv · 2024Multicenter Study, Observational Study
- SUPERA stent outcomes in Above-The-Knee IntervEntions: Effects of COMPression and ELongation (SAKE-COMPEL) Sub-study.
Bhatt H, Kovach R, Janzer S, et al. · Cardiovasc Revasc Med · 2018Comparative Study
Other devices of this type
Also filed under product code NIP.
- GORE VIABAHN EndoprosthesisW. L. Gore & Associates, Inc. · PMA 2022
- LifeStent Vascular Stent SystemBard Peripheral Vascular, Inc. · PMA 2023
- Everflex Self-Expanding Peripheral Stent System (Everflex)Medtronic Vascular, Inc. · PMA 2025
- Innova Vascular Self-Expanding Stent SystemBoston Scientific Corporation · PMA 2021
- BioMimics 3D Vascular Stent SystemVeryan Medical, Ltd. · PMA 2025
- Bard Lifestent Vascular Stent SystemBard Peripheral Vascular, Inc. · PMA 2016
- Astron Pulsar and Pulsar-18 Stent SystemsBiotronik AG · PMA 2018
- Misago Peripheral Self-Expanding Stent SystemTerumo Medical Corporation · PMA 2017
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.